within Pharmacolibrary.Drugs.ATC.C;

model C03DA03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.00013,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.143,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.001,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C03DA03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Canrenone is a synthetic steroid and an active metabolite of spironolactone. It acts as an aldosterone antagonist (mineralocorticoid receptor antagonist) and has diuretic and antihypertensive properties. It was previously used in the management of conditions such as hypertension, heart failure, and edema but is less commonly used today, having been replaced by other mineralocorticoid antagonists such as eplerenone or spironolactone.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult humans after oral administration.</p><h4>References</h4><ol><li><p>Ho, PC, et al., &amp; Heazlewood, V (1984). Pharmacokinetics of canrenone and metabolites after base hydrolysis following single and multiple dose oral administration of spironolactone. <i>European journal of clinical pharmacology</i> 27(4) 441–446. DOI:<a href=&quot;https://doi.org/10.1007/BF00549592&quot;>10.1007/BF00549592</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6519151/&quot;>https://pubmed.ncbi.nlm.nih.gov/6519151</a></p></li><li><p>Krause, W, et al., &amp; Seifert, W (1983). Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man. <i>European journal of clinical pharmacology</i> 25(4) 449–453. DOI:<a href=&quot;https://doi.org/10.1007/BF00542109&quot;>10.1007/BF00542109</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6653638/&quot;>https://pubmed.ncbi.nlm.nih.gov/6653638</a></p></li><li><p>Lass, J, et al., &amp; Lutsar, I (2024). Pharmacokinetics of oral spironolactone in infants up to 2 years of age. <i>European journal of clinical pharmacology</i> 80(2) 239–248. DOI:<a href=&quot;https://doi.org/10.1007/s00228-023-03599-w&quot;>10.1007/s00228-023-03599-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38041740/&quot;>https://pubmed.ncbi.nlm.nih.gov/38041740</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C03DA03;
